Login to Your Account

Huya, Eisai join forces in $280M deal for HDAC inhibitor HBI-8000

By Cornelia Zou
Staff Writer

Tuesday, February 2, 2016

HONG KONG – A promising cancer orphan drug could soon be available in a string of major and emerging Asian markets, marking the next step in a multinational partnership for global commercialization and research.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription